James E Flynn Insider Trading Transactions
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
Latest Insider Trading Transactions of James E Flynn
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: < prev 1 ... 3 4 5 6 7 8 9 10 10 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 15,145 | 15,599 | 894,213 | 909.4 K to 894.2 K (-1.67 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 9,429 | 9,712 | 696,597 | 706 K to 696.6 K (-1.34 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 6,028 | 6,209 | 374,710 | 380.7 K to 374.7 K (-1.58 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 19,081 | 19,463 | 1,464,934 | 1.5 M to 1.5 M (-1.29 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 11,844 | 12,081 | 909,358 | 921.2 K to 909.4 K (-1.29 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 7,367 | 7,514 | 705,996 | 713.4 K to 706 K (-1.03 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 4,708 | 4,802 | 380,738 | 385.4 K to 380.7 K (-1.22 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 4,052 | 4,093 | 1,484,015 | 1.5 M to 1.5 M (-0.27 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 2,514 | 2,539 | 921,202 | 923.7 K to 921.2 K (-0.27 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 1,564 | 1,580 | 713,363 | 714.9 K to 713.4 K (-0.22 %) |
| Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 1,000 | 1,010 | 385,446 | 386.4 K to 385.4 K (-0.26 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 124,688 | 124,688 | 1,573,653 | 1.7 M to 1.6 M (-7.34 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 77,399 | 77,399 | 976,841 | 1.1 M to 976.8 K (-7.34 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 48,135 | 48,135 | 747,966 | 796.1 K to 748 K (-6.05 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 30,779 | 30,779 | 407,568 | 438.3 K to 407.6 K (-7.02 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 7,192 | 7,192 | 1,698,341 | 1.7 M to 1.7 M (-0.42 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 4,464 | 4,464 | 1,054,240 | 1.1 M to 1.1 M (-0.42 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 2,777 | 2,777 | 796,101 | 798.9 K to 796.1 K (-0.35 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 1,774 | 1,774 | 438,347 | 440.1 K to 438.3 K (-0.40 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 21,741 | 21,524 | 1,705,533 | 1.7 M to 1.7 M (-1.26 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 13,495 | 13,360 | 1,058,704 | 1.1 M to 1.1 M (-1.26 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 4,694 | 4,694 | 798,878 | 803.6 K to 798.9 K (-0.58 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 3,000 | 3,000 | 440,121 | 443.1 K to 440.1 K (-0.68 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 12,159 | 12,159 | 1,727,274 | 1.7 M to 1.7 M (-0.70 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 7,547 | 7,547 | 1,072,199 | 1.1 M to 1.1 M (-0.70 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 8,394 | 8,310 | 803,572 | 812 K to 803.6 K (-1.03 %) |
| May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 5,365 | 5,311 | 443,121 | 448.5 K to 443.1 K (-1.20 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 11,667 | 11,550 | 1,488,067 | 1.5 M to 1.5 M (-0.78 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 7,242 | 7,170 | 923,716 | 931 K to 923.7 K (-0.78 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 4,504 | 4,459 | 714,927 | 719.4 K to 714.9 K (-0.63 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 2,879 | 2,850 | 386,446 | 389.3 K to 386.4 K (-0.74 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 19,836 | 19,638 | 1,499,734 | 1.5 M to 1.5 M (-1.31 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 12,312 | 12,189 | 930,958 | 943.3 K to 931 K (-1.31 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 7,657 | 7,580 | 719,431 | 727.1 K to 719.4 K (-1.05 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 4,895 | 4,846 | 389,325 | 394.2 K to 389.3 K (-1.24 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 54,083 | 54,624 | 1,519,570 | 1.6 M to 1.5 M (-3.44 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 33,571 | 33,907 | 943,270 | 976.8 K to 943.3 K (-3.44 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 20,878 | 21,087 | 727,088 | 748 K to 727.1 K (-2.79 %) |
| May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 13,348 | 13,481 | 394,220 | 407.6 K to 394.2 K (-3.28 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 23,092 | 25,632 | 1,739,433 | 1.8 M to 1.7 M (-1.31 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 14,334 | 15,911 | 1,079,746 | 1.1 M to 1.1 M (-1.31 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 8,915 | 9,896 | 811,966 | 820.9 K to 812 K (-1.09 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 5,698 | 6,325 | 448,486 | 454.2 K to 448.5 K (-1.25 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 34,061 | 37,808 | 1,762,525 | 1.8 M to 1.8 M (-1.90 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 21,143 | 23,469 | 1,094,080 | 1.1 M to 1.1 M (-1.90 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 13,149 | 14,595 | 820,881 | 834 K to 820.9 K (-1.58 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 8,406 | 9,331 | 454,184 | 462.6 K to 454.2 K (-1.82 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 74,913 | 83,903 | 1,796,586 | 1.9 M to 1.8 M (-4.00 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 46,501 | 52,081 | 1,115,223 | 1.2 M to 1.1 M (-4.00 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 28,919 | 32,389 | 834,030 | 862.9 K to 834 K (-3.35 %) |
| May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 18,489 | 20,708 | 462,590 | 481.1 K to 462.6 K (-3.84 %) |
| Jun 07 2011 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 8.00 | 301,424 | 2,411,392 | 3,204,167 | 2.9 M to 3.2 M (+10.38 %) |
| Jun 07 2011 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 8.00 | 229,252 | 1,834,016 | 2,279,997 | 2.1 M to 2.3 M (+11.18 %) |
| Jun 07 2011 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 8.00 | 72,800 | 582,400 | 762,700 | 689.9 K to 762.7 K (+10.55 %) |
| Jun 07 2011 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 8.00 | 46,524 | 372,192 | 470,425 | 423.9 K to 470.4 K (+10.98 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.20 | 24,765 | 401,193 | 3,035,472 | 3.1 M to 3 M (-0.81 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.20 | 18,835 | 305,127 | 2,303,811 | 2.3 M to 2.3 M (-0.81 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.35 | 3,409 | 55,737 | 3,060,237 | 3.1 M to 3.1 M (-0.11 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.35 | 2,591 | 42,363 | 2,322,646 | 2.3 M to 2.3 M (-0.11 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 30,887 | 505,620 | 3,063,646 | 3.1 M to 3.1 M (-1.00 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 23,490 | 384,531 | 2,325,237 | 2.3 M to 2.3 M (-1.00 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.39 | 86,166 | 1,412,261 | 3,094,533 | 3.2 M to 3.1 M (-2.71 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.39 | 65,534 | 1,074,102 | 2,348,727 | 2.4 M to 2.3 M (-2.71 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.36 | 17,259 | 282,357 | 3,180,699 | 3.2 M to 3.2 M (-0.54 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.36 | 13,126 | 214,741 | 2,414,261 | 2.4 M to 2.4 M (-0.54 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 14,201 | 231,192 | 3,197,958 | 3.2 M to 3.2 M (-0.44 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 10,799 | 175,808 | 2,427,387 | 2.4 M to 2.4 M (-0.44 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.38 | 39,231 | 642,604 | 3,212,159 | 3.3 M to 3.2 M (-1.21 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.38 | 29,837 | 488,730 | 2,438,186 | 2.5 M to 2.4 M (-1.21 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 5,681 | 92,998 | 3,251,390 | 3.3 M to 3.3 M (-0.17 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 4,319 | 70,702 | 2,468,023 | 2.5 M to 2.5 M (-0.17 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 6,249 | 102,296 | 3,257,071 | 3.3 M to 3.3 M (-0.19 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.37 | 4,751 | 77,774 | 2,472,342 | 2.5 M to 2.5 M (-0.19 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 14,622 | 238,631 | 3,263,320 | 3.3 M to 3.3 M (-0.45 %) |
| Apr 06 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 11,120 | 181,478 | 2,477,093 | 2.5 M to 2.5 M (-0.45 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.30 | 10,078 | 164,271 | 3,277,942 | 3.3 M to 3.3 M (-0.31 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.30 | 7,822 | 127,499 | 2,488,213 | 2.5 M to 2.5 M (-0.31 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 4,305 | 70,258 | 3,288,020 | 3.3 M to 3.3 M (-0.13 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 3,341 | 54,525 | 2,496,035 | 2.5 M to 2.5 M (-0.13 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 53,808 | 875,994 | 3,292,325 | 3.3 M to 3.3 M (-1.61 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 41,764 | 679,918 | 2,499,376 | 2.5 M to 2.5 M (-1.64 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 22,701 | 369,572 | 3,346,133 | 3.4 M to 3.3 M (-0.67 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.28 | 17,619 | 286,837 | 2,541,140 | 2.6 M to 2.5 M (-0.69 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 10,403 | 169,777 | 3,368,834 | 3.4 M to 3.4 M (-0.31 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.32 | 8,074 | 131,768 | 2,588,759 | 2.6 M to 2.6 M (-0.31 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.51 | 55,013 | 908,265 | 3,379,237 | 3.4 M to 3.4 M (-1.60 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.51 | 42,701 | 704,994 | 2,566,833 | 2.6 M to 2.6 M (-1.64 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.48 | 1,288 | 21,226 | 3,434,250 | 3.4 M to 3.4 M (-0.04 %) |
| Apr 01 2011 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Sell | S | 16.48 | 998 | 16,447 | 2,609,534 | 2.6 M to 2.6 M (-0.04 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 135,036 | 1,431,382 | 551,099 | 686.1 K to 551.1 K (-19.68 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 83,814 | 888,428 | 342,061 | 425.9 K to 342.1 K (-19.68 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 39,916 | 423,110 | 162,917 | 202.8 K to 162.9 K (-19.68 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 26,375 | 279,575 | 107,655 | 134 K to 107.7 K (-19.68 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 52,551 | 551,786 | 686,135 | 738.7 K to 686.1 K (-7.11 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 32,616 | 342,468 | 425,875 | 458.5 K to 425.9 K (-7.11 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 15,535 | 163,118 | 202,833 | 218.4 K to 202.8 K (-7.11 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 10,265 | 107,783 | 134,030 | 144.3 K to 134 K (-7.11 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.54 | 478,946 | 5,048,091 | 738,686 | 1.2 M to 738.7 K (-39.33 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.54 | 297,290 | 3,133,437 | 458,491 | 755.8 K to 458.5 K (-39.34 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.52 | 328,995 | 3,461,027 | 218,368 | 547.4 K to 218.4 K (-60.11 %) |
| May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.52 | 211,717 | 2,227,263 | 144,295 | 356 K to 144.3 K (-59.47 %) |
| Nov 05 2010 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 7.55 | 3,690 | 27,860 | 2,902,743 | 2.9 M to 2.9 M (-0.13 %) |
| Nov 05 2010 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 7.55 | 2,605 | 19,668 | 2,050,745 | 2.1 M to 2.1 M (-0.13 %) |
| Nov 05 2010 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 7.55 | 900 | 6,795 | 689,900 | 690.8 K to 689.9 K (-0.13 %) |
| Nov 05 2010 | RIGL | RIGEL PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 7.55 | 516 | 3,896 | 423,901 | 424.4 K to 423.9 K (-0.12 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.51 | 11,557 | 5,894 | 781,833 | 793.4 K to 781.8 K (-1.46 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.51 | 6,443 | 3,286 | 435,887 | 442.3 K to 435.9 K (-1.46 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.50 | 8,925 | 4,463 | 793,390 | 802.3 K to 793.4 K (-1.11 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.50 | 4,975 | 2,488 | 442,330 | 447.3 K to 442.3 K (-1.11 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.51 | 192,615 | 98,234 | 802,315 | 994.9 K to 802.3 K (-19.36 %) |
| Dec 14 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.51 | 107,385 | 54,766 | 447,305 | 554.7 K to 447.3 K (-19.36 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 20,995 | 12,177 | 994,930 | 1 M to 994.9 K (-2.07 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 11,705 | 6,789 | 554,690 | 566.4 K to 554.7 K (-2.07 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.56 | 88,905 | 49,787 | 1,015,925 | 1.1 M to 1 M (-8.05 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.56 | 49,565 | 27,756 | 566,395 | 616 K to 566.4 K (-8.05 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.60 | 290,692 | 174,415 | 1,104,830 | 1.4 M to 1.1 M (-20.83 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.60 | 162,064 | 97,238 | 615,960 | 778 K to 616 K (-20.83 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.55 | 1,011 | 556 | 1,395,522 | 1.4 M to 1.4 M (-0.07 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.55 | 563 | 310 | 778,024 | 778.6 K to 778 K (-0.07 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.56 | 128,003 | 71,682 | 1,396,533 | 1.5 M to 1.4 M (-8.40 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.56 | 71,362 | 39,963 | 778,587 | 849.9 K to 778.6 K (-8.40 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.53 | 10,209 | 5,411 | 1,524,536 | 1.5 M to 1.5 M (-0.67 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.53 | 5,691 | 3,016 | 849,949 | 855.6 K to 849.9 K (-0.67 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.59 | 193 | 114 | 1,534,745 | 1.5 M to 1.5 M (-0.01 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.59 | 107 | 63 | 855,640 | 855.7 K to 855.6 K (-0.01 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 34,724 | 20,140 | 1,534,938 | 1.6 M to 1.5 M (-2.21 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 19,358 | 11,228 | 855,747 | 875.1 K to 855.7 K (-2.21 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 4,816 | 2,793 | 1,569,662 | 1.6 M to 1.6 M (-0.31 %) |
| Nov 18 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 2,684 | 1,557 | 875,105 | 877.8 K to 875.1 K (-0.31 %) |
| Oct 28 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.59 | 63,563 | 37,502 | 1,574,478 | 1.6 M to 1.6 M (-3.88 %) |
| Oct 28 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.59 | 35,437 | 20,908 | 877,789 | 913.2 K to 877.8 K (-3.88 %) |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Option Exercise | X | 12.50 | 1,736 | 21,700 | 0 | |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Option Exercise | X | 12.50 | 1,399 | 17,488 | 0 | |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Option Exercise | X | 11.00 | 1,244 | 13,684 | 0 | |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Option Exercise | X | 11.00 | 942 | 10,362 | 0 | |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Buy | X | 12.50 | 173,600 | 2,170,000 | 3,435,538 | 3.3 M to 3.4 M (+5.32 %) |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Buy | X | 12.50 | 139,900 | 1,748,750 | 2,610,532 | 2.5 M to 2.6 M (+5.66 %) |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Buy | X | 11.00 | 124,400 | 1,368,400 | 3,261,938 | 3.1 M to 3.3 M (+3.96 %) |
| Oct 19 2010 | MDCO | MEDICINES CO /DE | Flynn James E | 10% Owner | Buy | X | 11.00 | 94,200 | 1,036,200 | 2,470,632 | 2.4 M to 2.5 M (+3.96 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 26.00 | 246 | 6,396 | 346,016 | 346.3 K to 346 K (-0.07 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 26.00 | 154 | 4,004 | 210,662 | 210.8 K to 210.7 K (-0.07 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 25.00 | 82,954 | 2,073,850 | 346,242 | 429.2 K to 346.2 K (-19.33 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 25.00 | 51,646 | 1,291,150 | 210,816 | 262.5 K to 210.8 K (-19.68 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 25.00 | 58,639 | 1,465,975 | 429,216 | 487.9 K to 429.2 K (-12.02 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 25.00 | 36,538 | 913,450 | 262,462 | 299 K to 262.5 K (-12.22 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 26.00 | 739 | 19,214 | 487,855 | 488.6 K to 487.9 K (-0.15 %) |
| Dec 13 2010 | HITK | HI TECH PHARMACAL ... | Flynn James E | 10% Owner | Sell | S | 26.00 | 461 | 11,986 | 299,000 | 299.5 K to 299 K (-0.15 %) |
| Sep 28 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 129 | 75 | 1,638,041 | 1.6 M to 1.6 M (-0.01 %) |
| Sep 28 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 71 | 41 | 913,226 | 913.3 K to 913.2 K (-0.01 %) |
| Sep 28 2010 | NURO | NeuroMetrix, Inc. | Flynn James E | 10% Owner | Sell | S | 0.58 | 12,842 | 7,448 | 1,638,170 | 1.7 M to 1.6 M (-0.78 %) |